{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T14:57:28Z","timestamp":1772117848696,"version":"3.50.1"},"reference-count":33,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2005,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Caspofungin is a parenteral antifungal that inhibits beta-1,3-\n            <jats:sc>d<\/jats:sc>\n            -glucan synthesis. Although licensed for adult use, the appropriate caspofungin dosing regimen in pediatric patients is not yet known. We therefore investigated the pharmacokinetics and safety of caspofungin in pediatric patients. Thirty-nine children (ages 2 to 11 years) and adolescents (ages 12 to 17 years) with neutropenia were administered caspofungin using either a weight-based regimen (1 mg\/kg of body weight\/day) or a body surface area regimen (50 mg\/m\n            <jats:sup>2<\/jats:sup>\n            \/day or 70 mg\/m\n            <jats:sup>2<\/jats:sup>\n            \/day). Plasma samples for caspofungin profiles were collected on days 1 and 4. These results were compared to those from adults treated with either 50 or 70 mg\/day for mucosal candidiasis. In children receiving 1 mg\/kg\/day (maximum, 50 mg\/day), the area under the concentration-time curve over 24 h (AUC\n            <jats:sub>0-24<\/jats:sub>\n            ) was significantly smaller (46% after multiple doses) than that observed in adults receiving 50 mg\/day (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.001). In children and adolescents receiving 50 mg\/m\n            <jats:sup>2<\/jats:sup>\n            \/day (maximum, 70 mg\/day), the AUC\n            <jats:sub>0-24<\/jats:sub>\n            following multiple doses was similar to that for the exposure in adults receiving 50 mg\/day. The AUC\n            <jats:sub>0-24<\/jats:sub>\n            and concentration trough (at 24 h) in pediatric patients receiving the 50-mg\/m\n            <jats:sup>2<\/jats:sup>\n            daily regimen were consistent across the range of ages. Caspofungin was generally well tolerated in this study. None of the patients developed a serious drug-related adverse event or were discontinued for toxicity. These results demonstrate that caspofungin at 1 mg\/kg\/day in pediatric patients is suboptimal. Caspofungin administration at 50 mg\/m\n            <jats:sup>2<\/jats:sup>\n            \/day provides a comparable exposure to that of adult patients treated with 50 mg\/day.\n          <\/jats:p>","DOI":"10.1128\/aac.49.11.4536-4545.2005","type":"journal-article","created":{"date-parts":[[2005,10,26]],"date-time":"2005-10-26T16:37:59Z","timestamp":1130344679000},"page":"4536-4545","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":207,"title":["Pharmacokinetics, Safety, and Tolerability of Caspofungin in Children and Adolescents"],"prefix":"10.1128","volume":"49","author":[{"given":"Thomas J.","family":"Walsh","sequence":"first","affiliation":[{"name":"National Cancer Institute, Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter C.","family":"Adamson","sequence":"additional","affiliation":[{"name":"Children's Hospital of Pennsylvania, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nita L.","family":"Seibel","sequence":"additional","affiliation":[{"name":"Children's National Medical Center, Washington, D.C."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia M.","family":"Flynn","sequence":"additional","affiliation":[{"name":"St. Jude Children's Research Hospital, Memphis, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael N.","family":"Neely","sequence":"additional","affiliation":[{"name":"Rainbow Babies &amp; Children Hospital, Cleveland, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Johns Hopkins Hospital\u2014Baystate, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aziza","family":"Shad","sequence":"additional","affiliation":[{"name":"Georgetown Hospital, Washington, D.C."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheldon L.","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Texas Children's Hospital, Houston, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen M.","family":"Roden","sequence":"additional","affiliation":[{"name":"National Cancer Institute, Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie A.","family":"Stone","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, West Point, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alisha","family":"Miller","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, West Point, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan K.","family":"Bradshaw","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, West Point, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan X.","family":"Li","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, West Point, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carole A.","family":"Sable","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, West Point, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas A.","family":"Kartsonis","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, West Point, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.11.2333"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.4.1187-1192.2003"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.2.451-457.2002"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/323335"},{"key":"e_1_3_2_6_2","first-page":"302","volume":"18","year":"1999","unstructured":"Barchiesi, F., A. M. Schimizzi, A. W. Fothergill, G. Scalise, and M. G. Rinaldi. 1999. In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species. Eur. J. Clin. Microbiol. Infect. Dis.18:302-304.","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.11.2326"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.112.3.634"},{"key":"e_1_3_2_9_2","first-page":"S15","volume":"18","year":"1996","unstructured":"Chanock, S., and T. Walsh. 1996. Evolving concepts of prevention and treatment of invasive fungal infections in pediatric bone marrow transplant recipients. Bone Marrow Transplant.18(Suppl. 3):S15.","journal-title":"Bone Marrow Transplant."},{"key":"e_1_3_2_10_2","first-page":"S78","volume":"21","year":"1998","unstructured":"Engelhard, D. 1998. Bacterial and fungal infections in children undergoing bone marrow transplantation. Bone Marrow Transplant.21(Suppl. 2):S78.","journal-title":"Bone Marrow Transplant."},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3109\/10428199309148562","volume":"10","year":"1993","unstructured":"Flynn, P. M., N. M. Marina, G. K. Rivera, and W. T. Hughes. 1993. Candida tropicalis infections in children with leukemia. Leuk. Lymphoma10:369-376.","journal-title":"Leuk. Lymphoma"},{"key":"e_1_3_2_12_2","first-page":"747","volume":"22","year":"2002","unstructured":"Franklin, J. A., J. McCormick, and P. M. Flynn. 2002. Retrospective study of the safety of caspofungin in immunocompromised pediatric patients. Pediatr. Infect. Dis. J.22:747-749.","journal-title":"Pediatr. Infect. Dis. J."},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00126334-200210010-00009","volume":"31","year":"2002","unstructured":"Kartsonis, N., M. J. DiNubile, K. Bartizal, P. S. Hicks, D. Ryan, and C. A. Sable. 2002. Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. J. Acquir. Immune Defic. Syndr.31:183-187.","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"e_1_3_2_14_2","first-page":"69","volume":"49","year":"2002","unstructured":"Leibovitz, E. 2002. Neonatal candidosis: clinical picture, management controversies and consensus, and new therapeutic options. J. Antimicrob. Chemother.49(Suppl. 1):69-73.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/clinids\/14.2.485","volume":"14","year":"1992","unstructured":"Leibovitz, E., A. Iuster-Reicher, M. Amitai, and B. Mogilner. 1992. Systemic candidal infections associated with use of peripheral venous catheters in neonates: a 9-year experience. Clin. Infect. Dis.14:485-491.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1086\/423381"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.5.1277"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021585"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198710223171717"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0011-393X(03)00019-5","volume":"64","year":"2003","unstructured":"Neely, M., and J. Blumer. 2003. Pharmacokinetic characteristics of caspofungin in two pediatric liver transplant patients. Curr. Ther. Res.64:127-136.","journal-title":"Curr. Ther. Res."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/02681219780001291"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.1.12-23.2002"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199811000-00008"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3062.2002.01004.x"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-2670(97)00263-8"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.3.739-745.2002"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.3.815-823.2004"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1086\/323401"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01191-9"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-002-0822-1"},{"key":"e_1_3_2_31_2","first-page":"187","volume":"11","year":"1996","unstructured":"Walsh, T., C. Gonzalez, C. Lyman, S. Chanock, and P. Pizzo. 1996. Invasive fungal infections in children: recent advances in diagnosis and treatment. Adv. Pediatr. Infect. Dis.11:187-290.","journal-title":"Adv. Pediatr. Infect. Dis."},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040446"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1086\/424465"},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1200\/JCO.1990.8.2.280","volume":"8","year":"1990","unstructured":"Wiley, J. M., N. Smith, B. Leventhal, M. L. Graham, L. C. Strauss, C. A. Hurwitz, J. Modlin, D. Mellits, R. Baumgardner, and B. J. Corden. 1990. Invasive fungal infections in pediatric leukemic patients with fever and neutropenia during induction chemotherapy: a multivariate analysis of risk factors. J. Clin. Oncol.8:280-286.","journal-title":"J. Clin. Oncol."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.49.11.4536-4545.2005","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.49.11.4536-4545.2005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T18:37:46Z","timestamp":1645468666000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.49.11.4536-4545.2005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["10.1128\/AAC.49.11.4536-4545.2005"],"URL":"https:\/\/doi.org\/10.1128\/aac.49.11.4536-4545.2005","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11]]},"assertion":[{"value":"2004-08-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2005-03-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2005-11-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}